tbuckley/cabot-search huggingface dataset:
A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
Authors: J.K. Litton, M. Scoggins, D.L. Ramirez, R.K. Murthy, G.J. Whitman, K.R. Hess, B.E. Adrada, S.L. Moulder, C.H. Barcenas, V. Valero, D. Booser, J. Schwartz Gomez, G.B. Mills, H. Piwnica-Worms, B.K. Arun
Journal: Annals of Oncology (2016)
CSIG-23. CYTOPLASMIC RNA STRESS GRANULES: A PUTATIVE TRANSLATIONAL MECHANISM OF mTOR REGULATION IN GLIOBLASTOMA
Authors: Adrienne Weeks, Scott Whitehouse, Aaron Robichaud, Sameer Agnihotri, Christian Smith, James Rutka
Journal: Neuro-Oncology (2016)

We performed RNA immunoprecipitation followed by microarray profiling of mRNAs pulled down by Stress Granule (SG) markers TIAR and G3BP1 in normal and oxidative stress conditions to enrich for mRNA contained in SGs during stress in Glioblastoma cell lines. Interestingly, components of the mTOR Ragulator, RRAGD and LAMTOR were enriched in G3BP1 precipitates in stress conditions. We confirmed localization of RRAGD mRNA to SGs utilizing single molecule RNA FISH in arsenite stressed Glioblastoma cell lines. We therefore hypothesized that perhaps Ragulator mRNAs are sheltered in SG for rapid translation after stress release. We confirmed that protein levels of RRAGD and LAMTOR increase at 25-35 minutes post-release from arsenite induced stress concomitant with a 50% decrease in SGs. We also observed similar increases in protein levels of other Ragulator components (RRAGA/B/C). This increase differed from protein levels of other mRNAs identified in our screen, which showed no increase in protein levels after stress release (TIAM1, WAVE1/2, FOXK2, FOXN3). The increase in protein levels of the Ragulator complex components remained despite the addition of actinomycin D, suggesting that the increase protein levels are a result of translation of a stabilized cohort of mRNA and not de novo transcription. Interestingly, preliminary data utilizing a mCherry-LAMP construct suggests that mTOR colocalizes to the lysosome at 25-35 minutes post release from stress, a necessary step for mTOR activation. Utilizing Glioblastoma cells that we have engineered to display a delay in SG dissolution, we aim to demonstrate impaired SG release of mRNA results in a shift in the Ragulator protein spike after stress release. Taken together this data suggests a novel translational control mechanism of mTOR activation by SGs.
P08.28 Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation
Authors: F. Pessina, P. Navarria, A. Ascolese, L. Cozzi, S. Tomatis, M. Riva, M. Simonelli, M. Scorsetti, L. Bello
Journal: Neuro-Oncology (2016)
Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques
Authors: Eileen M Boyle, Julie Lejeune, Salomon Manier, Lucile Musset, Claire Bories, Remy Dulery, Stéphanie Guidez, Sarah Bonnet, Guillemette Fouquet, Brigitte Onraed, Jean-Luc Faucompré, Sabine Tricot, Stephanie Poulain, Veronique Leblond, Xavier Leleu, Stephen Harding
Journal: Blood (2014)
Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study
Authors: Xiao-Hui Zhang, Ru Feng, Lan-ping Xu, Qian Jiang, Hao Jiang, Hai-xia Fu, Hui Liu, Ting Niu, Xin Wang, Jian-da Hu, Ming Jiang, Zhao Wang, Jing-wen Wang, Hui Ma, Yan-di Xie, Xiao-lu Zhu, Hao Wang, Lai Wei, Xiao Jun Huang
Journal: Blood (2014)
Cause-specific mortality after follicular non-Hodgkin lymphoma: a report from the Spanish Lymphoma Study Group (GOTEL)
Authors: M. Provencio, A. Royuela, J. Gomez Codina, M. Torrente, P. Sabin, M. Llanos, J. Guma I. Padro, C. Quero, A. Blasco, M.A. Cruz
Journal: Annals of Oncology (2016)
METB-04. THE ROLE OF INTEGRIN IN METABOLIC REPROGRAMING IN GLIOBLASTOMAS
Authors: Karyn Ding, Pulin Che
Journal: Neuro-Oncology (2016)

It is known that many types of cancer cells have growth advantage over normal cells by utilizing glucose at a high rate and undergoing aerobic glycolysis. However, the underlying mechanisms contributing to the glucose metabolism reprograming have not been well defined. Human malignant astrocytoma cells express integrin alpha-V-beta-3 (αvβ3) and the expression of integrin αvβ3 has been linked to neoangiogenesis and cell migration in high-grade glioma periphery. Here, we determined whether integrin αv has a novel role acting as an intrinsic driver to promote aerobic glycolysis and tumorigenesis through metabolic reprograming. Blocking integrin αV decreases intracellular glucose levels and induces cell migration reduction and cell detachment. Glucose assays demonstrated that integrin αV promotes glucose consumption and glucose-to-lactate conversion in human malignant astrocytoma cells. Extracellular flux analysis indicates that integrin αV enhances glycolysis and decreases mitochondrial respiration in human malignant astrocytoma cells. These observations establish an important role of integrin αV in human Glioblastomas (GBM) glucose metabolism through alterations in the OXPHOS-to-glycolysis balance and metabolic reprograming.
The power of traditional prognostic factor and immunohistochemical (IHC) surrogate molecular subtypes of breast cancer (BC) in predicting neoadjuvant chemotherapy response: results of a retrospective study
Authors: G. Manna, F.S. Di Lisa, I. Speranza, T. Losanno, A. Giuli, A. Emiliani, A. Prete, A. Prelaj, S. Pecorari, J.R. Giron Berrios, C. Fusto, P. Seminara
Journal: Annals of Oncology (2016)
PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in a human colorectal cancer model
Authors: S. Napolitano, B. Valentina, E. Martinelli, V. Sforza, P.P. Vitiello, F. De Vita, N. Zanaletti, P. Vitale, D. Ciardiello, F. Morgillo, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2016)
NIMG-55. SIMULTANEOUS QUANTITATIVE PH MAPPING AND HYPOXIA IMAGING USING FAST MULTI-ECHO AMINE CEST-EPI IN HUMAN GLIOMAS
Authors: Robert Harris, Linda Liau, Kevin Leu, Phioanh Nghiemphu, Whitney Pope, Albert Lai, Timothy Cloughesy, Benjamin Ellingson
Journal: Neuro-Oncology (2016)

Extracellular acidosis and significant amino acid uptake are hallmarks of gliomas. Chemical exchange saturation transfer (CEST) MRI targeted the amine protons on amino acids can serve as a combined amino acid and pH-weighted biomarker with a high specificity for active tumor. We have recently developed a fast, multi-echo CEST-EPI sequence that can provide quantitative T2 maps and hypoxia-weighted images simultaneously with pH-weighted data. This new technique, combined with a comprehensive simulation of the MR physics, allows for estimation of quantitative pH values and relative oxygen extraction fraction (rOEF). We hypothesize this approach will be useful for therapeutic monitoring in patients with glioma. A comprehensive clinical CEST simulation was used to obtain optimal scan parameters for pH-weighted CEST-EPI in glioma tissues. Using these parameters, multi-echo amine CEST-EPI data was collected in 12 glioma patients. Quantitative pH maps were calculated for these patients and compared to perfusion and rOEF maps. Optimization of CEST simulation parameters indicated short saturation pulse trains of high amplitude Gaussian pulses are ideal for obtaining fast pH-weighted contrast when focusing on amine protons. Quantitative pH maps provided complimentary information to perfusion, PET, and rOEF images and reflected underlying pathophysiology. Multi-echo amine CEST-EPI provides simultaneous information about acidity, hypoxia, and water concentration (T2) from a single image acquisition in patients with gliomas. This information may be valuable for non-invasive characterization of tumor biology in human gliomas.
Identification of Iron Agglomerates by T2* MRI In Major Organs of Patients with End-Stage Renal Disease Who Receive Regularly Erythropoietin with Intravenous Iron
Authors: Hussam Ghoti, Orly Goitein, Raid Jaber, ze’Ev Katzir, Eli Konen, Ramon Simon-Lopez, Eliezer A. Rachmilewitz
Journal: Blood (2010)
Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant
Authors: Y. Tanabe, S. Shiraishi, D. Nishizawa, A. Hamada, J. Hasegawa, Y. Ozaki, N. Tamura, A. Shimomura, M. Yunokawa, K. Yonemori, T. Takano, H. Kawabata, K. Ikeda, K. Tamura, Y. Fujiwara, C. Shimizu
Journal: Annals of Oncology (2016)
The gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for proper use of S-1 and tegafur-uracil /leucovorin in preoperative chemoradiotherapy in patients with rectal cancer
Authors: S. Sadahiro, T. Suzuki, A. Tanaka, K. Okada, G. Saito, A. Kamijo, H. Nagase
Journal: Annals of Oncology (2016)
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
Authors: Weixing Shen, Joshua L. Plotkin, Veronica Francardo, Wai Kin D. Ko, Zhong Xie, Qin Li, Tim Fieblinger, Jürgen Wess, Richard R. Neubig, Craig W. Lindsley, P. Jeffrey Conn, Paul Greengard, Erwan Bezard, M. Angela Cenci, D. James Surmeier
Journal: Neuron (2016)
131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Authors: John M. Pagel, Frederick R. Appelbaum, Brenda M. Sandmaier, Joseph G. Rajendran, Ted Gooley, Darrell R. Fisher, Eneida Nemecek, Ajay K. Gopal, Michael B. Maris, Katherine Ruffner, Dana C. Matthews, H. Joachim Deeg, David G. Maloney, Paul J. Martin, Rainer Storb
Journal: Blood (2005)
Quantification of genetic variants as marker of Brca-like phenotype in ovarian cancer
Authors: J. Garcia-Donas, N. Lainez Milagro, E.M. Guerra Alia, M. Garrido, R. Guarch, A. Acosta, A. Herrador, M. Prieto Pozuelo, J.F. Rodriguez-Moreno
Journal: Annals of Oncology (2016)
Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).
Authors: Marzia Varettoni, Alessandro Corso, Gianmatteo Pica, Patrizia Zappasodi, Silvia Mangiacavalli, Cristiana Pascutto, Mario Lazzarino
Journal: Blood (2007)
NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS
Authors: Benjamin Ellingson, Lauren Abrey, Josep Garcia, Olivier Chinot, Dana Aftab, Gisela Schwab, Cedric Revil, Frank Saran, Ryo Nishikawa, Roger Henriksson, Colin Hessel, Robert Harris, Davis Woodworth, Kevin Leu, Albert Lai, Solmaz Sahebjam, Whitney Pope, Warren Mason, Wolfgang Wick, Patrick Wen, Timothy Cloughesy
Journal: Neuro-Oncology (2016)

The prognostic significance of residual or baseline contrast enhancing tumor volume prior to initiation of chemotherapy in both newly diagnosed and recurrent GBM for OS remains controversial, particularly in the context of surgical resection and or use of anti-angiogenic therapy. In the current study we pooled 1,535 GBM patients, 1,038 newly diagnosed and 497 after 1-2 recurrences, from several single and multicenter chemotherapy and anti-angiogenic therapy clinical trials (AVAglio, BRAIN, and XL184-201). A central core lab quantified tumor volume using enhancing disease plus central necrosis from T1 subtraction maps to remove blood products and other artifacts. Data suggest that baseline tumor volume is a strong prognostic factor for OS in all therapeutic scenarios besides patients who previously failed anti-angiogenic therapy. In newly diagnosed GBM, a post-surgical residual enhancing tumor volume less than the median, 10mL (~1.34 cm diameter), was associated with a significant survival advantage independent of age and therapy (P<0.0001, HR=1.624, 95%C.I.=1.48-1.94). In recurrent GBM, a baseline tumor volume prior to 2nd or 3rd line therapy less than the median, 15mL (~1.53 cm in diameter), was associated with a significant survival advantage independent of age and therapy (P<0.0001, HR=1.773, 95%C.I.=1.48-2.23). Comparisons within treatment arms, molecular classifications, and methylation status will also be presented. Results support the hypothesis that contrast-enhancing tumor is a surrogate biomarker for active disease as evidenced by prognostic significance in almost every therapeutic context. Results suggest clinical trial treatment arms must have a balanced distribution of tumor size and tumor size should be considered when interpreting therapeutic efficacy.
DISTRIBUTION OF LIPID CORE RICH PLAQUES IN CORONARY BIFURCATIONS ASSESSED BY NEAR-INFRARED SPECTROSCOPY
Authors: Jung Ho Heo, Salvatore Brugaletta, Hector M Garcia-Garcia, Sanneke H. De boer, Cihan Simsek, Eric Boersma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2012)
Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).
Authors: Anna Vanazzi, Pier Francesco Ferrucci, Chiara Grana, Giancarlo Pruneri, Cristiano Crosta, Antonello Pinto, Marco Chinol, Giovanni Paganelli, Giovanni Martinelli
Journal: Blood (2007)
Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance Is Very Effective In Early Relapsed/Refractory MM
Authors: Massimo Offidani, Claudia Polloni, Laura Corvatta, Silvia Gentili, Anna Mele, Marino Brunori, Rita Rizzi, Massimo Catarini, Arduino Samori, Nicola Blasi, Mario Ferranti, Lara Malerba, Patrizia Caraffa, Pietro Leoni
Journal: Blood (2010)
P01.01 Ectopic expression of microRNA-1300 in adult and paediatric glioma cells induces cytokinesis failure and apoptosis via ECT2
Authors: M. Boissinot, H. King, M. Adams, J. Higgins, L. P. Steele, H. Wurdak, J. Bond, D. C. Tomlinson, S. E. Lawler, S. C. Short
Journal: Neuro-Oncology (2016)

This is a repository copy of Ectopic expression of microRNA-1300 in adult and paediatric glioma cells induces cytokinesis failure and apoptosis via ECT2.
The predictive role of peripheral blood lymphocytes (PBLs) immunophenotype in patients with advanced non-small-cell lung cancer (NSCLC) and renal-cell carcinoma (mRCC) undergoing nivolumab: preliminary results
Authors: F. Nelli, M.A. Fabbri, D. Padalino, V. Panichi, G. D'Auria, M.G. Chilelli, C. Signorelli, F. Primi, M. Montanaro, E.M. Ruggeri
Journal: Annals of Oncology (2016)
Decrease of Malignant Potential of t(8;21) Positive Cells after Stable Expression of RUNX-CBFA2T1-Specific Small Interfering RNA.
Authors: Bettina Drescher, Kerstin Goerlich, Dagmar Reile, Gerhard Heil, Olaf Heidenreich, Katharina Wagner, Arnold Ganser, Juergen Krauter
Journal: Blood (2004)
Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
Authors: N. Kotecki, A. Le Cesne, E. Tresch-Bruneel, O. Mir, C. Chevreau, F. Bertucci, C. Delcambre, E. Saada-Bouzid, S. Piperno-Neumann, J.-O. Bay, I.L. Ray-Coquard, T. Ryckewaert, N. Isambert, A. Italiano, S. Clisant, J.-Y. Blay, N. Penel
Journal: Annals of Oncology (2016)
IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma
Authors: Shubham Pandey, Frédéric Mourcin, Tony Marchand, Saba Nayar, Marion Guirriec, Céline Pangault, Céline Monvoisin, Patricia Amé-Thomas, Fabien Guilloton, Joelle Dulong, Mark Coles, Thierry Fest, Anja Mottok, Francesca Barone, Karin Tarte
Journal: Blood (2017)
NIMG-75. FEATURES OF LOCAL GRADIENT DISORDER ON MRI THAT DISTINGUISH RADIATION NECROSIS AND TUMOR RECURRENCE POST-RADIOTHERAPY ARE ASSOCIATED WITH ZONAL NECROSIS, VESSEL WALL THICKENING, HYALINIZATION AND DEMYELINATION: A PRELIMINARY STUDY IN BRAIN TUMORS
Authors: Prateek Prasanna, Lisa Rogers, Mark Cohen, Gagandeep Singh, Chaitra Badve, Leo Wolansky, Anant Madabhushi, Pallavi Tiwari
Journal: Neuro-Oncology (2016)

Distinguishing radiation necrosis (RN), from tumor recurrence (RT) on routine MRI is a challenging clinical problem in neuro-oncology. We have recently shown success in distinguishing RT and RN on MRI via CoLlAGe, a new computer extracted image feature that captures localized gradient disorder within a lesion. The objective of this study is to understand the histopathologic and morphologic basis of CoLlAGe in distinguishing RT from RN. 3T MRI studies (Gd-T1w, T2w, FLAIR) and surgical resection specimens were obtained from 34 brain tumor patients: 20 primary (10 RN, 10 RT) and 14 (5 RN, 9 RT) metastatic studies, at least 9-months post-radiation. Histological traits including vessel-wall thickening, demyelination, vascular hyalinization and zonal necrosis were graded by an expert neuropathologist. A ‘score’ between 0 and 4 was assigned based on the percentage of each of the observed attributes on the surgical specimens. Necrotic, enhancing tumor and peritumoral regions were independently delineated by a neuroradiologist on the 3 MRI sequences. 13 CoLlAGe features (e.g. entropy, variance, correlation) were computed for every region for each protocol. A pair-wise Spearman correlation was performed between each feature and the pathologic ‘score’. For primary neoplasms, CoLlAGe features from enhancing Gd-T1w were significantly (p<0.05) associated with zonal necrosis and vessel wall thickening. CoLlAGe features on FLAIR hyperintensities were associated with demyelination. For metastatic cases, vascular hyalinization was significantly associated with 9 of the 13 CoLlAGe features from peritumoral FLAIR regions. Imaging correlates on routine MRI were identified for histological attributes (zonal necrosis, vessel wall thickening, vascular hyalinization and demyelination) observed in RN and RT on surgically resected specimens. These histological attributes contribute to lesion heterogeneity, and may be reflected in the CoLlAGe features at the radiologic scale.
Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)
Authors: R. Giampieri, M. Scartozzi, B. Daniele, D. Ferrari, S. Lonardi, A. Zaniboni, L. Cavanna, G. Rosati, N. Pella, M.G. Zampino, P. Sozzi, L. Casula, S. Rota, D. Germano, M. Puzzoni, C. Loretelli, V. Zagonel, R. Labianca, L. Frontini, S. Cascinu
Journal: Annals of Oncology (2016)
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Authors: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica Bauman, Lucian R. Chirieac, Thomas A. D'Amico, Malcolm M. DeCamp, Thomas J. Dilling, Michael Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes
Journal: Journal of the National Comprehensive Cancer Network (2017)

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
ACTR-48. A MULTICENTER, 500-PATIENT, PROSPECTIVE OBSERVATIONAL REGISTRY OF THE PERFORMANCE OF CARMUSTINE WAFERS FOR CNS MALIGNANCIES
Authors: Timothy Ryken, Evan Scullin, Kris Smith, Kevin Lillehei
Journal: Neuro-Oncology (2016)

While the goal is to improve survival times without adding toxicity, decisions involving treatment modalities for grade III and IV CNS tumors remain complicated. Placed in a brain tumor-resection cavity, carmustine wafers provide controlled release of a local antineoplastic agent to treat residual cancer cells while limiting systemic toxicities. Despite the availability of carmustine wafers for 20 years, large-scale analysis of this FDA-approved treatment in contemporary practice has been lacking. The Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) registry will assess the long-term safety and effectiveness of carmustine wafers in current practice by enrolling up to 500 patients with various brain tumor types with 3 years of follow-up. Patients enrolled in the VIGILANT registry (NCT02684838) must be at least 18 years of age and have no medical condition that puts them at increased risk by participation in the registry. During 3 years of follow-up, patients will receive usual care from treating physician(s) in routine quarterly visits, with no registry-specific visits required. At office visits, patients will be asked to complete the Functional Assessment of Cancer Therapy-Brain questionnaire about well-being, and clinicians will be asked to assess patients using the Karnofsky Performance Scale index. Effectiveness endpoints are overall and progression-free survival. Patients will be analyzed by tumor type and by the status of such biomarkers as methyl guanine methyl transferase (MGMT) methylation, epidermal growth factor receptor (EGFR) amplification, and isocitrate dehydrogenase (IDH) 1 and 2 mutation. Safety endpoints are all serious adverse events and suspected adverse drug interactions. Initial data from the VIGILANT registry, describing patient characteristics, perioperative outcomes, and patterns of use with carmustine wafers, will be analyzed and presented. With a large enrollment and long-term follow-up, the VIGILANT registry may help define brain-tumor patient subgroups that best benefit from carmustine wafers.
Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease
Authors: S.L. Moulder, J.K. Litton, E. Mittendorf, W. Yang, N. Ueno, K.R. Hess, V. Valero, R.K. Murthy, N. Ibrahim, B. Lim, B.K. Arun, A. Thompson, H. Piwnica-Worms, D. Tripathy, W.F. Symmans
Journal: Annals of Oncology (2016)
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival
Authors: Massimo Breccia, Luigiana Luciano, Roberto Latagliata, Fausto Castagnetti, Dario Ferrero, Francesco Cavazzini, Malgorzata Monika Trawinska, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Elena Crisà, Pellegrino Musto, Antonella Gozzini, Laura Cavalli, Enrico Montefusco, Alessandra Iurlo, Sabina Russo, Michele Cedrone, Antonella Russo Rossi, Patrizia Pregno, Mauro Endri, Antonio Spadea, Gianfranco Giglio, Francesca Celesti, Federica Sorà, Sergio Storti, Ada M D'Addosio, Giovanna Rege Cambrin, Elisabetta Abruzzese, Gianantonio Rosti, Giuliana Alimena
Journal: Blood (2011)